HTA17 Cost-Effectiveness Analysis of Capivasertib Plus Fulvestrant in Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Advanced Breast Cancer: A US Payer Perspective
Abstract
Authors
X Liang CJ Tan B Yu D.C. Malone